Charles Schwab Investment Management Inc. Trims Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Charles Schwab Investment Management Inc. trimmed its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 11.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,147,370 shares of the company’s stock after selling 150,272 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.45% of Lyell Immunopharma worth $1,583,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in shares of Lyell Immunopharma by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock valued at $974,000 after purchasing an additional 38,487 shares during the last quarter. TD Asset Management Inc increased its stake in Lyell Immunopharma by 4.2% in the 2nd quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock valued at $1,457,000 after buying an additional 40,800 shares during the period. American Century Companies Inc. boosted its holdings in Lyell Immunopharma by 18.1% in the 2nd quarter. American Century Companies Inc. now owns 279,425 shares of the company’s stock valued at $405,000 after purchasing an additional 42,752 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Lyell Immunopharma by 197.8% in the second quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock valued at $58,000 after acquiring an additional 26,635 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Lyell Immunopharma by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 553,163 shares of the company’s stock valued at $802,000 after buying an additional 69,712 shares in the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on LYEL shares. Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their price target for the company from $6.00 to $1.00 in a report on Wednesday, October 30th. HC Wainwright restated a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Tuesday, November 12th.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $0.67 on Tuesday. Lyell Immunopharma, Inc. has a 1 year low of $0.65 and a 1 year high of $3.26. The stock’s 50-day simple moving average is $1.04 and its 200-day simple moving average is $1.42. The firm has a market cap of $195.87 million, a price-to-earnings ratio of -0.85 and a beta of -0.45.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The company had revenue of $0.03 million during the quarter. As a group, research analysts predict that Lyell Immunopharma, Inc. will post -0.8 EPS for the current year.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.